e-learning
resources
Vienna 2003
Monday 29.09.2003
Clinical pathobiology in diffuse and in neoplastic disorders
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Heterogeneous reactivity of ICAM-1 on alveolar macrophages (AMs) in patients with non-small cell lung cancer (NSCLC)
M. Dabrowska, H. Grubek-Jaworska, J. J. Domagala-Kulawik, G. Hoser, R. Krenke, P. Nejman, R. Chazan (Warsaw, Poland)
Source:
Annual Congress 2003 - Clinical pathobiology in diffuse and in neoplastic disorders
Session:
Clinical pathobiology in diffuse and in neoplastic disorders
Session type:
Thematic Poster Session
Number:
1687
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Dabrowska, H. Grubek-Jaworska, J. J. Domagala-Kulawik, G. Hoser, R. Krenke, P. Nejman, R. Chazan (Warsaw, Poland). Heterogeneous reactivity of ICAM-1 on alveolar macrophages (AMs) in patients with non-small cell lung cancer (NSCLC). Eur Respir J 2003; 22: Suppl. 45, 1687
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Cytotoxicity and apotosis of alveolar lymphocytes (AL) in early clinical stage (I-IIa) of non-small cell lung cancer (NSCLC)
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018
Expression of the intercellular adhesion molecule ICAM-1 on alveolar macrophages in healthy subjects and non-small cell lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 276s
Year: 2002
Tumour infiltrating lymphocytes and tumour associated macrophages in chronic obstructive pulmonary disease (COPD) patients with non-small cell lung cancer (NSCLC) and in patients with NSCLC
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro
Year: 2020
Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10
Source: Eur Respir J 2007; 30: 608-610
Year: 2007
Gene expression profiles in non-small cell lung cancer (NSCLC) and lung tissue in smokers and non-smokers
Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer
Year: 2009
Cytotoxic phenotype of lymphocytes in bronchoalveolar lavage (BAL) of patients with non-small cell lung cancer (NSCLC)
Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench
Year: 2017
Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer
Source: Eur Respir J 2007; 30: 627-632
Year: 2007
Relationship between blood monocyte subsets with activation markers and macrophages in non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Comparing exhaled molecular profiles of patients with non-small cell lung cancer (NSCLC) with those of patients with non-pulmonary malignancy
Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease
Year: 2010
The prognostic influence of tumor infiltrating M1 and M2 phenotype macrophages in resected non-small cell lung cancer
Source: International Congress 2016 – Lung cancer immunology: latest research
Year: 2016
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Differential cytokine expression in non-small cell lung carcinomas
Source: Eur Respir J 2007; 30: Suppl. 51, 512s
Year: 2007
Soluble non-invasive markers in non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 459s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept